• Reuters


A drug once hailed as Japan’s biggest contribution in the global fight against COVID-19 suffered another setback on Friday, as Fujifilm Holdings Corp. said it was halting enrollment in a clinical trial of the pill, Avigan.

The emergence of the omicron variant of coronavirus, which usually causes milder infections, made it tough to determine the drug’s effectiveness in preventing severe symptoms, the company said in a statement.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.